Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study.

@article{Sawyers2002ImatinibIH,
  title={Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study.},
  author={Charles L Sawyers and Andreas Hochhaus and Eric J. Feldman and John M. Goldman and Carole B. Miller and Oliver G Ottmann and Charles A Schiffer and Moshe Talpaz and François Guilhot and Michael Werner Nikolaus Deininger and Thomas Fischer and Steve G O'Brien and Richard M Stone and Carlo B Gambacorti-Passerini and Nigel H. Russell and Jose J. Reiffers and Thomas Charles Shea and Bernard Chapuis and Steven E. Coutr{\'e} and Sante Tura and Enrica Morra and Richard A Larson and Alan Saven and Christian Peschel and Alois A Gratwohl and Franco Mandelli and Monique Ben-Am and Insa Gathmann and Renaud Capdeville and Ronald L. Paquette and Brian J. Druker},
  journal={Blood},
  year={2002},
  volume={99 10},
  pages={3530-9}
}
Blast crisis is the most advanced stage of chronic myelogenous leukemia (CML) and is highly refractory to therapy. CML is caused by expression of the chimeric BCR-ABL tyrosine kinase oncogene, the product of the t(9;22) Philadelphia translocation. Imatinib (Glivec, formerly STI571) is a rationally developed, orally administered inhibitor of the Bcr-Abl tyrosine kinase. A total of 260 patients with CML were enrolled in a phase II trial, of whom 229 had a confirmed diagnosis of CML in blast… CONTINUE READING